I hold these stock.

DYOH (do your own homework.)

To-day there was a slight drop in price, but number of analysts are giving favourable reports.

What triggered my interest was better than expected results and if I am right looking at charts it shows an inverted head and shoulders. Hopefully a good sign. Also the current rate of Share price growth is about 90% pa over the last 5weeks. This is unlikely to continue indefinitely but SP could hit 850p over next few weeks.

To-day at close, there were some large buys of about 5million shares. 40million approx.

Another trigger for me was the following which should increase earnings.

Aviva to form JV in Taiwan with First FinancialAFX
LONDON (Thomson Financial) - Aviva PLC, the UK's largest insurer, said it has entered into a joint venture with First Financial Holding Co Ltd to sell insurance and pension products in Taiwan. The joint venture company, First-Aviva, will distribute long-term savings and pension products in Taiwan through an exclusive agreement with First Financial's flagship unit, First Commercial Bank. Aviva, which will have a 49 pct stake in the joint venture, added that the initial paid up capital of the new company will be 34 mln stg.First Commercial Bank is Taiwan's second largest bank network, with five mln retail customers, it added.TFN.newsdesk@thomson.comkkb/faj/slm




Date: Wednesday 25 Apr 2007
LONDON (ShareCast) - If the message gets home that Aviva will not bid for Prudential, the stock should rebound strongly, especially if Aviva can sustain its current impressive performance. There is still work to be done but, at 794.5p, the shares are a strong buy says the Independent.
Date: Tuesday 24 Apr 2007
LONDON (ShareCast) - Aviva stood out among the risers on a tough day for blue chip stocks. The life insurer posted an upbeat first quarter statement with brokers pleased with the numbers.



DYOH

Panmure Gordon Buy 479.15 660.00 660.00 Retains

Finals http://www.moneyam.com/action/news/showArticle?id=5230479 Market likes them, SP up over 5%.

RBC Capital Markets Underperform 488.05 460.00 480.00 Reiterates

Here is exciting news.

Broker Forecast - Barclays Capital issues a broker note on Aviva PLC

BFN

Barclays Capital today reaffirms its overweight investment rating on Aviva PLC (LON:AV.) and raised its price target to 664p (from 663p).

Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its overweight investment rating on Aviva PLC (LON:AV.) and cut its price target to 584p (from 594p).

Some support here closing the gaps on the way down. I just seem to be fixated with gaps lately :0) No position watching.

LATEST BROKER VIEWS

Date Broker New target Recomm.
22 Mar JP Morgan... 584.00 Overweight
18 Mar Barclays... 664.00 Overweight
17 Mar HSBC 550.00 Hold
14 Mar RBC Capital... 480.00 Underperform
11 Mar Societe... 690.00 Buy
11 Mar Beaufort... N/A Buy
11 Mar Deutsche Bank 610.00 Buy
11 Mar JP Morgan... 594.00 Overweight
10 Mar Panmure Gordon 660.00 Buy
7 Mar Deutsche Bank 610.00 Buy
Broker Recommendations for Aviva

Well looks like the above was the obvious trade gaps nearly closed. What isn't obvious, what happens next? Tending towards lower. Watching

LATEST BROKER VIEWS

Date Broker New target Recomm.
24 Mar Exane BNP... 440.00 Underperform
24 Mar Berenberg 440.00 Sell

LATEST BROKER VIEWS

Date Broker New target Recomm.
24 Mar Exane BNP... 440.00 Underperform
24 Mar Berenberg 440.00 Sell

Disappointment coming for Aviva investors
Insurer Aviva (AV) is an expensive stock and analysts can see ‘disappointments looming’.

Berenberg analyst Trevor Moss retained his ‘sell’ recommendation and target price of 440p on the shares, which fell 3.3% to 457.1p yesterday.

‘Aviva’s reported figures have been heavily flattered in recent years,’ he said. ‘While it is true that restructuring can bring one-off benefits, by definition these eventually run out and should not be included in price/earnings or sustainable return on equity calculation. In our estimations, underlying earnings for Aviva have actually been going backwards. We cannot foresee any significant improvements.’

Moss added that Aviva’s ‘very mature book means it is running fast to stand still’ and he ‘does not buy into the capital return story’.

He said the stock is expensive and also ‘expensive against peers, both UK life companies and European composites’.

‘Even on consensus earnings numbers, the European composites look better value. We continue to see disappointments looming and believe that the downgrade cycle for this stock has only just begun.’

Photo 2 of 6Previous

Ex-Divi next Thursday 07/04.

Can anybody clarify which sector AV. is in Life Assurance or Non Life Assurance, not that it matters much today both sectors struggling. Many moons ago spent hours placing stocks in their sectors and placed AV. in Non-Life Assurance was I right? No longer subscribe to MAM (cheap scate) so can't check stock screener. Be obliged thanks.

About us

Thanks skinny. Doh!!! why didn't i think of that LOL!!!

:0) Thick scouser syndrome.

JP Morgan Cazenove today reaffirms its overweight investment rating on Aviva PLC (LON:AV.) and raised its price target to 596p (from 584p).

Jefferies International today reaffirms its buy investment rating on Aviva PLC (LON:AV.) and cut its price target to 523p (from 568p).

Broker Forecast - Canaccord Genuity issues a broker note on Aviva PLC

BFN

Canaccord Genuity today reaffirms its buy investment rating on Aviva PLC (LON:AV.) and cut its price target to 550p (from 600p).

--=-=-=

Large institutional buy, Check RNS.




-=-==

Have a look at fundamental projections, but charts don't look that enticing to me.

Yield is nice.

I hold.

Fred - it looks like Oncimmune only floated 2 days ago - so an entry level for AV.

Skinny,

Thanks.


Still holding with overall profit.

W/S